Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma

Histopathology

Volumn 59, Issue 6, 2011, Pages 1249-1260

  Pula, Bartosz ^a,b   Jethon, Aleksandra ^a,b   Piotrowska, Aleksandra ^a,b   Gomulkiewicz, Agnieszka ^a,b   Owczarek, Tomasz ^c   Calik, Jacek ^d   Wojnar, Andrzej ^d   Witkiewicz, Wojciech ^b   Rys, Janusz ^e   Ugorski, Maciej ^c,f   Dziegiel, Piotr ^a,b,d,g   Podhorska Okolow, Marzena ^a,b  

^a Medical University   (Poland)

^b Regional Specialist Hospital   (Poland)

^c WROCLAW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

^d Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^g POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Breast cancer; Cancer associated fibroblasts; Podoplanin

Indexed keywords

KI 67 ANTIGEN; PODOPLANIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; BREAST INVASIVE DUCTAL CARCINOMA; CANCER ASSOCIATED FIBROBLAST; CANCER CELL CULTURE; CANCER INVASION; CANCER SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FIBROBLAST; FIBROCYSTIC BREAST DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84855926096     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04060.x     Document Type: Article

References (36)

1. Farr AG, Berry ML, Kim A et al. Characterization and cloning of a novel glycoprotein expressed by stromal cells in T-dependent areas of peripheral lymphoid tissues. J. Exp. Med. 1992; 176; 1477-1482.
2. Gandarillas A, Scholl FG, Benito N et al. Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol. Carcinog. 1997; 20; 10-18.
3. Zimmer G, Oeffner F, Von Messling V et al. Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium. Biochem. J. 1999; 341; 277-284.
4. Kato Y, Fujita N, Kunita A et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J. Biol. Chem. 2003; 278; 51599-51605.
5. Schacht V, Ramirez MI, Hong YK et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 2003; 22; 3546-3556.
6. Schacht V, Dadras SS, Johnson LA et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am. J. Pathol. 2005; 166; 913-921.
7. Sonne SB, Herlihy AS, Hoei-Hansen CE et al. Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1A-2, podoplanin) in human developing testis, testicular carcinoma insitu and germ-cell tumours. Virchows Arch. 2006; 449; 200-206.
8. Martín-Villar E, Scholl FG, Gamallo C et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int. J. Cancer 2005; 113; 899-910.
9. Wicki A, Lehembre F, Wick N et al. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006; 9; 261-272.
10. Mishima K, Kato Y, Kaneko MK et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 2006; 111; 483-488.
11. Kadota K, Huang CL, Liu D et al. The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer. Lung Cancer 2010; 70; 88-93.
12. Cueni LN, Hegyi I, Shin JW et al. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am. J. Pathol. 2010; 177; 1004-1016.
13. Martín-Villar E, Megías D, Castel S et al. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J. Cell Sci. 2006; 119; 4541-4553.
14. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411; 375-379.
15. Allinen M, Beroukhim R, Cai L et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6; 17-32.
16. Orimo A, Gupta PB, Sgroi DC et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121; 335-348.
17. Kuperwasser C, Chavarria T, Wu M et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl Acad. Sci. USA 2004; 101; 4966-4971.
18. Boire A, Covic L, Agarwal A et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120; 303-313.
19. Sternlicht MD, Lochter A, Sympson CJ et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999; 98; 137-146.
20. Kawase A, Ishii G, Nagai K et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int. J. Cancer 2008; 123; 1053-1059.
21. Yamanashi T, Nakanishi Y, Fujii G et al. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology 2009; 77; 53-62.
22. Aishima S, Nishihara Y, Iguchi T et al. Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Mod. Pathol. 2008; 21; 256-264.
23. Sappino AP, Skalli O, Jackson B et al. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer 1988; 41; 707-712.
24. Kitano H, Kageyama S, Hewitt SM et al. Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. Arch. Pathol. Lab. Med. 2010; 134; 1520-1527.
25. Colpaert CG, Vermeulen PB, Fox SB et al. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res. Treat. 2003; 81; 137-147.
26. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 2009; 20; 1319-1329.
27. Vermeulen PB, Gasparini G, Fox SB et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer 2002; 38; 1564-1579.
28. Breiteneder-Geleff S, Soleiman A, Kowalski H et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am. J. Pathol. 1999; 154; 385-394.
29. Kreppel M, Scheer M, Drebber U et al. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch. 2010; 456; 473-482.
30. Rahadiani N, Ikeda J, Makino T et al. Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann. Surg. Oncol. 2010; 17; 1311-1323.
31. Rodrigo JP, García-Carracedo D, González MV et al. Podoplanin expression in the development and progression of laryngeal squamous cell carcinomas. Mol. Cancer 2010; 9; 48-56.
32. Shen Y, Chen CS, Ichikawa H et al. SRC induces podoplanin expression to promote cell migration. J. Biol. Chem. 2010; 285; 9649-9656.
33. Ordóñez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum. Pathol. 2005; 36; 372-380.
34. Kato Y, Kaneko M, Sata M et al. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol. 2005; 26; 195-200.
35. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15years. Br. J. Cancer 1957; 11; 359-377.
36. Elston CW. Grading of invasive carcinoma of the breast. In Page DL, Andreson TJ eds. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987; 300-311.